MorphoSys AG (MORG.DE)

About

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietar... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	0.78
Market Cap(Mil.):	€2,171.58
Shares Outstanding(Mil.):	29.35
Dividend:	--
Yield (%):	--

Financials

	MORG.DE	Industry	Sector
P/E (TTM):	--	69.71	34.39
EPS (TTM):	-2.61	--	--
ROI:	-19.28	9.01	14.96
ROE:	-19.78	10.15	16.52

Latest News about MORG.DE

German stocks - Factors to watch on Nov. 16

BERLIN, Nov 16 The following are some of the factors that may move German stocks on Friday:

16 Nov 2018

German stocks - Factors to watch on September 13

BERLIN, Sept 13 The following are some of the factors that may move German stocks on Thursday:

13 Sep 2018

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

19 Jul 2018

Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

ZURICH, July 19 Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

19 Jul 2018

German stocks - Factors to watch on July 11

BERLIN/FRANKFURT, July 11 The following are some of the factors that may move German stocks on Wednesday:

11 Jul 2018

» More MORG.DE News